{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:10:55Z","timestamp":1758042655566,"version":"3.44.0"},"reference-count":19,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Peripheral artery disease (PAD) is a common atherosclerotic vascular condition associated with many complications. The specific effect of angiotensin receptor blockers (ARBs) on the short-term complications in PAD patients has not been explored before.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>This study aimed to evaluate the association between ARBs use and the disease severity, progression, the frequency of surgical interventions, and arterial occlusion rates among users.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A retrospective cohort study was conducted at King Abdullah \u2161 Hospital, including 133 patients followed between 2019 and 2024. The cohort was divided into two groups based on their exposure to ARBs: the ARBs group and the control group. Data related to patient demographics, clinical characteristics, medical history, laboratory results, vital signs, in addition to clinical outcomes were extracted from electronic medical records. Statistical analysis was performed using SPSS version 27.0.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>Among the participants, 24.8% experienced amputation, with 21.1% in the control group compared to 3.8% in the ARBs group. ARBs group has 79.2% lower Limb amputation (P-value 0.011; OR= 0.208, 95% CI 0.062\u20130.700) and 71% lower likelihood of having advanced PAD stage (stages III and IV) (P-value\u2009=\u20090.034, OR= 0.294, 95% CI\u2009=\u20090.095\u20130.911) compared to the control group. Linear regression analysis showed that the ARBs group has a decreased frequency of revascularization procedures (P-value 0.025;95% CI \u22121.004 \u2013 - 0.068).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>ARBs may serve as a promising protective treatment option for PAD patients, potentially benefiting disease progression by lowering the risk of amputation and reducing the need for revascularization procedures.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0330522","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:30:12Z","timestamp":1757611812000},"page":"e0330522","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of angiotensin receptor blockers on peripheral artery disease progression: A retrospective cohort study in Jordan"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0738-0640","authenticated-orcid":true,"given":"Mahar Zaid","family":"Kasasbeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eilaf Mohammad","family":"Al-Rabab\u02c8ah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawand A.","family":"Khasawneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8957-4135","authenticated-orcid":true,"given":"Fadi N.","family":"Asfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samah F.","family":"Al-Shatnawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nour A.","family":"Al-Sawalha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"issue":"9","key":"pone.0330522.ref001","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American heart association","volume":"144","author":"MH Criqui","year":"2021","journal-title":"Circulation"},{"issue":"7","key":"pone.0330522.ref002","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1161\/ATVBAHA.120.312862","article-title":"Vascular regeneration in peripheral artery disease","volume":"40","author":"JP Cooke","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"pone.0330522.ref003","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/0003319707302494","article-title":"The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients","volume":"58","author":"P Poredos","year":"2007","journal-title":"Angiology"},{"issue":"7","key":"pone.0330522.ref004","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41569-021-00663-9","article-title":"Update on the pathophysiology and medical treatment of peripheral artery disease","volume":"19","author":"J Golledge","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"24","key":"pone.0330522.ref005","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"149","author":"HL Gornik","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"pone.0330522.ref006","first-page":"14","article-title":"Updates in medical management of peripheral artery disease","volume":"27","author":"A Ahmad","year":"2025","journal-title":"Curr Treat Opt Cardiovas Med"},{"issue":"3","key":"pone.0330522.ref007","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1358863X15574321","article-title":"Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia","volume":"20","author":"EJ Armstrong","year":"2015","journal-title":"Vasc Med"},{"issue":"6","key":"pone.0330522.ref008","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jvs.2020.02.041","article-title":"Improved survival with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic limb-threatening ischemia","volume":"72","author":"SZ Khan","year":"2020","journal-title":"J Vasc Surg"},{"key":"pone.0330522.ref009","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/VHRM.S137698","article-title":"Use of angiotensin-converting enzyme inhibitors and freedom from amputation after lower extremity revascularization","volume":"13","author":"JE Kray","year":"2017","journal-title":"Vasc Health Risk Manag"},{"issue":"6","key":"pone.0330522.ref010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/ehjcvp\/pvaa026","article-title":"Impact of angiotensin receptor blockers on mortality after hospitalization for symptomatic lower extremity artery disease","volume":"7","author":"F-X Lap\u00e9bie","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"5","key":"pone.0330522.ref011","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1524-475X.2010.00624.x","article-title":"The differential effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with respect to foot ulcer and limb amputation in those with diabetes","volume":"18","author":"DJ Margolis","year":"2010","journal-title":"Wound Repair Regen"},{"key":"pone.0330522.ref012","article-title":"Effects of valsartan on restenosis in patients with arteriosclerosis obliterans of the lower extremities undergoing interventional therapy: a prospective, randomized, single-blind trial","volume":"26","author":"W Yao","year":"2020","journal-title":"Med Sci Monit"},{"issue":"1","key":"pone.0330522.ref013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvs.2024.09.008","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with improved amputation-free survival in chronic limb-threatening ischemia","volume":"81","author":"N Elsayed","year":"2025","journal-title":"J Vasc Surg"},{"key":"pone.0330522.ref014","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.2147\/IJGM.S322417","article-title":"The impact of chronic kidney disease on peripheral artery disease and peripheral revascularization","volume":"14","author":"R Serra","year":"2021","journal-title":"Int J Gen Med"},{"issue":"14","key":"pone.0330522.ref015","article-title":"Effect of different classes of antihypertensive drugs on endothelial function and inflammation","volume":"20","author":"IVG Silva","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"pone.0330522.ref016","doi-asserted-by":"crossref","first-page":"9771","DOI":"10.1038\/s41598-022-13772-3","article-title":"Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects","volume":"12","author":"AY Tehrani","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"pone.0330522.ref017","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1055\/s-0034-1393976","article-title":"Overview of classification systems in peripheral artery disease","volume":"31","author":"RL Hardman","year":"2014","journal-title":"Semin Intervent Radiol"},{"issue":"7","key":"pone.0330522.ref018","article-title":"Incidence and factors associated with major amputation in patients with peripheral artery disease: insights from the EUCLID trial","volume":"13","author":"CA Long","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"5","key":"pone.0330522.ref019","first-page":"560","article-title":"Canadian cardiovascular society 2022 guidelines for peripheral arterial disease","volume":"38","author":"BL Abramson","year":"2022","journal-title":"Can J Cardiol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:30:17Z","timestamp":1757611817000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330522"}},"subtitle":[],"editor":[{"given":"Hean Teik","family":"Ong","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0330522","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2025,9,11]]}}}